Biopharma · FDA Approvals · Stock

IMMP Immutep

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immun…

Assets on file: eftilagimod alfa

Start live analysis of IMMP Run 8-agent AI analysis Stock overview All sector events →

Catalyst calendar

Dated catalysts for IMMP, including recently decided ones.

June 2027

Jun 2027

~ Jun 2027

IMMPImmutep

eftilagimod alfa: Phase 3 trial NCT06726265 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

August 2028

Aug 2028

~ Aug 2028

IMMPImmutep

eftilagimod alfa: Phase 2 trial NCT07102940 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

Recent first-hand events

Every first-hand event for IMMP, newest first.

Instant stream — events appear as soon as they are filed.

Notable

Apr 15, 2026

12:00 PM

IMMPImmutep

Immutep receives FDA ODD for efti in soft tissue sarcoma

FDA granted Orphan Drug Designation to eftilagimod alfa for soft tissue sarcoma. Designation provides regulatory support, tax credits, fee exemptions, and seven years of market exclusivity upon approval. Designation is based on Phase II EFTISARC-NEO data showing 51.5% median tumour hyalinization/fibrosis versus 35% target.

FDA designationCompany press release